Clinical Trials
10 trialsNCT07079475 2026-05-26
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT06618287 2026-05-07
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07535437 2026-04-21
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05785741 2026-04-06
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Recruiting
NCT04665206 2026-04-02
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
Phase 1/2 Recruiting
NCT04486833 2026-01-21
Acclaim-1
Genprex, Inc.
Phase 1/2 Recruiting
NCT07206498 2025-11-28
WAYWIN103
Wayshine Biopharm, Inc.
Phase 1/2 Recruiting
NCT06071013 2025-01-23
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
Phase 1/2 Recruiting
NCT06306456 2024-07-08
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
Suzhou Genhouse Bio Co., Ltd.
Phase 1/2 Recruiting
NCT06109558 2024-05-30
PROFILE
Hunan Province Tumor Hospital
Phase 1/2 Recruiting